UNSPSC 51432511: Perindopril erbumine

This classification denotes an ace inhibitor with the molecular formula C19H32N2O5.C4H11N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1964X464OJ, chemically known as 1h-indole-2-carboxylic acid, 1-(2-((1-(ethoxycarbonyl)butyl)amino)-1-oxopropyl)octahydro-, (2s-(1(r*(r*)),2alpha,3abeta,7abeta))-, compd. with 2-methyl-2-propanamine (1:1) but more generally known as perindopril erbumine, which bears US NIH Compound Identifier 60183.

UNSPSC 51432511 Perindopril erbumine is a Commodity code tracking a specific generic cardiac medication used in emergency medical and pharmacy benefit programs by state and local health agencies. State and local governments procure this and related cardiac medications (including labetalol, epinephrine, adenosine, and diltiazem) primarily through two channels: emergency medical services supply contracts and multistate pharmaceutical cooperative purchasing agreements. Issuing bodies include city fire and rescue departments, state health and human services agencies, and cooperative purchasing alliances administering statewide or multistate pharmacy benefit programs. The work involves competitive bidding for pharmaceutical manufacturing and distribution to public emergency responders and health agencies, with vendors required to meet cGMP and DSCSA compliance, maintain expiration-date and shelf-life standards, provide Safety Data Sheets, and arrange logistics including pickup and replacement of expired stock.

Recent activity spans Florida, Texas, and Minnesota. The City of Tampa's Purchasing Department issued an IFB (Bid No. 26P00188) in April 2026 for Advanced Life Support Medications to supply Tampa Fire Rescue, with a response deadline of April 8, 2026 and an estimated contract value of $40,000, requiring firm pricing and ten-day delivery with a Small Local Business Enterprise sheltered-market 5 percent bid discount. The Texas Health and Human Services Commission posted an RFI (HHS0017013) in March 2026 exploring direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and wholesaler channels, signaling potential future procurement redesign. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP (S1070000015802) in January 2026 for generic multi-source pharmaceuticals and OTC products across participating states including Oregon, with proposals due March 26, 2026 and awards effective July 1, 2026, requiring vendors to work through three authorized wholesalers and maintain specific insurance coverage and manufacturing certifications.